Enterprise Value

546M

Cash

200.5M

Avg Qtr Burn

-22.76M

Short % of Float

9.74%

Insider Ownership

9.77%

Institutional Own.

86.16%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
4D-150 Details
Wet age-related macular degeneration

Phase 2

Data readout

4D-150 Details
Diabetic macular edema

Phase 2

Data readout

4D-710 Details
Cystic fibrosis

Phase 2

Initiation

4D-125 Details
X-linked retinitis pigmentosa

Phase 1/2

Data readout

4D-310 Details
Fabry disease

Phase 1/2

Data readout

4D-110 Details
Choroideremia

Phase 1

Data readout